By Rachel Mumby and Brian Cordery
We reported recently that the IPCom Guidelines which set out when the English Court should stay patent actions pending EPO oppositions appear to be “More honour’d in the breach than the observance”. This had been in response to the decision of Arnold J of 10 July 2014 who had refused to grant such a stay despite relatively broad undertakings offered by the patentee in relation to such a stay.
In the postscript to the above judgment, Arnold J noted that after he had released his judgment in draft, the patentee, Pharmacia, had offered two additional undertakings to Actavis, the potential infringer, in return for a stay. In a new judgment, handed down [...]
It is perhaps a poor reflection on the CJEU that it regularly issues rulings that, when the case is restored before the referring court, lead both parties to an action to claim victory. However this happened yet again when Warren J was given the unenviable task of implementing one of the trio of references decided by the CJEU last December in the world of SPCs.
Most readers will already be familiar with the facts of the Eli Lilly v HGS case. HGS has a patent directed to Neutrokine-alpha which includes a claim to antibodies which bind to this protein. This claim is drawn at a fairly broad level – anything that binds specifically to the full length Neutrokine-alpha polypeptide or the extra [...]
In a decision dated 11th July 2014, the English Patents Court (Arnold J.) has again refused to stay proceedings to revoke an EP(UK) whilst opposition proceedings are on-going at the EPO. The decisive factor in this decision seems again to have been the lengthy duration of the EPO proceedings. However, the undertakings offered by the patentee were such that it is considered that it will be a rare occasion when English proceedings are stayed despite the Court of Appeal guidelines indicating that this should be the default option.
The facts before the Court were quite simple: Pharmacia is the owner of a patent for sustained release dosage forms of pramipexole, a drug used in the treatment o [...]
By Brian Cordery and Rachel Mumby
Computer games enthusiasts will be interested in this decision from the English High Court in which it was found that the Nintendo Wii and Wii U systems infringe two patents owned by Philips. And for those with World Cup Football fever… one of Philips’ experts had previously done research which showed that in Geoff Hurst’s controversial goal in the 1966 World Cup Football final, the whole of the ball did not cross the whole of the line.
There were three patents in issue. The first (EP’484) relates to “modelling a virtual body in a virtual environment” i.e. Wii games where the player stands/runs on a “Balance Board” in order to control move [...]
The development of Herceptin (trastuzumab) in the late 1980s and 1990s is one of the most remarkable advances in the treatment of breast cancer. The story of the drug and its pioneer, the “velvet jackhammer”, Dennis Slamon, is neatly summarised in Siddhartha Mukherjee’s award winning novel: “The Emperor of All Maladies – a Biography of Cancer” – a fascinating if not necessarily uplifting read.
In short, unlike traditional chemotherapy, trastuzumab is a monoclonal antibody which specifically targets a receptor known as HER-2 which is involved in the development of breast cancer. No-one disputes that the development of Herceptin was a landmark advance in the field of oncology – [...]
by Katie Hutchinson & Brian Cordery
A recent judgment from Mr Justice Roth in the UK Patents Court found a patent for a fire resistant LED downlight valid and infringed. The gist of the invention was said to be a simple change from the state of the art but it was held that just because it was a simple change that did not preclude it from being inventive. On novelty, the one cited piece of prior art was held not to describe something which if performed would “necessarily lead to the making of the subject-matter of the patent” and thus not an anticipation according to the law as most recent stated by the House of Lords in the Synthon case back in 2005. Further, the prior art documents c [...]